Low-Dose Rapamycin Senescence Maintenance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of aging processes is limited, leading to inadequate prevention and treatment methods for age-related diseases, with existing approaches focusing on inhibiting senescence rather than maintaining it to prevent age-related disorders.
Innovation Solution
The use of low doses of rapamycin or its analogs, along with glucose restriction and AMPK activators, to maintain senescence and stimulate mitochondrial function, thereby preventing deterioration of senescent cells and treating age-related diseases by targeting the TOR/AMPK/mitochondrial pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional approaches focus on inhibiting senescence to treat age-related diseases, then the understanding of aging processes is limited, but the effectiveness of prevention and treatment methods is inadequate
Solution Approach 1:
The patent inverts the conventional approach by shifting from inhibiting senescence to maintaining senescence. Instead of trying to reverse or block cellular aging, the invention promotes and sustains the senescent state through TOR inhibition and AMPK activation, thereby improving treatment effectiveness while gaining new insights into aging processes.
Solution Approach 2:
The patent changes the therapeutic parameter from senescence inhibition to senescence maintenance. By modifying the target parameter from preventing cellular aging to sustaining it, the invention achieves better therapeutic outcomes and expands understanding of aging mechanisms through the TOR/AMPK/mitochondrial pathway.
2Reliability
If high doses of rapamycin are used to inhibit TOR pathway, then anti-aging effect is enhanced, but cell growth inhibition and toxicity increase
Solution Approach 1:
The patent applies partial action by using low doses of rapamycin that are sufficient to activate AMPK and maintain senescence without causing excessive TOR inhibition. This partial activation achieves the desired anti-aging effect while avoiding the harmful side effects of high-dose treatment, such as severe cell growth inhibition and toxicity.
Solution Approach 2:
The patent introduces AMPK as an intermediary mechanism. Instead of directly inhibiting TOR with high doses of rapamycin, the invention uses low-dose rapamycin to indirectly activate AMPK, which then mediates the anti-aging effects. This intermediary approach reduces direct TOR pathway suppression and its associated harmful effects.
3Stability of the object's composition
If senescent cells are allowed to deteriorate, then natural aging process occurs, but age-related diseases develop and cell death increases
Solution Approach 1:
The patent applies preliminary anti-action by preventing the deterioration of senescent cells before it leads to age-related diseases. Through TOR inhibition and AMPK activation, the invention counteracts the natural deterioration process, maintaining cellular stability and preventing the transition from controlled senescence to pathological aging and cell death.
Solution Approach 2:
The patent takes preliminary action by maintaining senescent cells in a stable state through pharmacological intervention. By acting on the TOR/AMPK pathway before deterioration occurs, the invention prevents the development of age-related diseases and preserves cell survival, thereby improving health status while respecting the natural aging process.
Data Source
AI summary
The present invention discloses novel mechanisms in the aging process and describes novel methods for high-throughput screening to identify, detect, and purify agents to be used for improving mitochondrial function, maintaining the cell cycle-arrested state in senescent and post mitotic cells, and thus preventing or treating age-related diseases or disorders associated with accelerated mitochondrial function loss, telomere dysfunction, and/or deterioration of the growth-arrested state. The present invention also discloses a number of compounds or compositions identified from this method. The present invention further provides the use of low doses of rapamycin or its analogs as a mimic of caloric restriction in preventing age-related diseases or disorders.